Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Rarbar99on Sep 28, 2021 10:24am
74 Views
Post# 33930143

RE:RE:Is anyone paying attention?

RE:RE:Is anyone paying attention?

Your first post on this forum is "Hey guys, I am new to ATE.."

this was back when ATE pumped to $5.50 and you were trying to chase the pump. You got caught holding the bag and now you're still here and making up lies.

 

Inthepez wrote: Damn you are stup!d lmao. How does that comment in anyway indicate I got in 2020. Lmao. Especially when I said my entry was low enough. And you’re assuming I never took profits. Like I said you’re a clown 

Id say nice try but it really was terrible. Go back to school. But let me guess you dropped out because you’re a a great investor, and love to show off daddy’s car lmao.
 

Rarbar99 wrote:

First Pez tried to claim he's making money on this stock because he bought during the 2017 price levels.

when I exposed him and showed him proof that he bought his shares starting in February 2020 (when this stock was $5.50) he quickly changed the fact and tried to say he sold most of those shares. 


but pezzy, what happened to the cheap shares you bought in the 2017 price levels? We don't care if you sold them or not, all we care about is HOW you got them when you clearly started investing in ate in February 2020.

the answer is clear. He was lying.

and this is him pumping this stock just 3 weeks before it crashed 80%.. yet he claims to have sold. Yeah right.

"We should be above $10 easily. Biggest drawback to ATE is not uplisting to the Nasdaq. Everyone go message antibe about this. At the end of the day, the science can’t be denied. Companies take 1 step forward and 2 back, and still end up on top. Some don’t. Do your own risk assessment. But entry is low enough that I don’t give af. "
 





<< Previous
Bullboard Posts
Next >>